A prospective evaluation of subconjunctival injection of @entity2995 for resistant XXXX .

@entity1 @entity32 @entity2995 @entity548 @entity39 @entity229 @entity134 @entity2790 @entity3170 @entity2713
PURPOSE: Prospective evaluation of the efficacy and safety of subconjunctival @entity2713 injections for resistant, nonnecrotizing, @entity3170 . DESIGN: Prospective, noncomparative, interventional case series. @entity1 : Twelve eyes of 10 consecutive @entity1 seen in the Doheny Eye Institute between August 1999 and December 2000 with diffuse, nonnecrotizing @entity3170 that was resistant to systemic antiinflammatory therapy. Eyes with a history of @entity134 response were excluded. INTERVENTION: Subconjunctival injection of @entity2995 to the areas of maximal @entity32 . MAIN OUTCOME MEASURES: @entity3170 activity, adverse treatment effects, and number of systemic medications required at the end of the follow-up period. RESULTS: Within 1 to 14 days after injection, complete resolution of signs and symptoms was achieved in 11 eyes and partial resolution in 1 eye. Two @entity1 had one recurrence each, 2.5 and 11 months after injection. Six of 10 @entity1 were able to discontinue all systemic therapy ( @entity229 +/- immunosuppressive drugs); the remaining 4 needed continued oral therapy for systemic indications. Transient @entity2790 and @entity548 occurred in one eye each. Median follow-up period was 15 months. No eye developed @entity39 . CONCLUSIONS: Subconjunctival injection of @entity2995 is a safe and effective treatment for resistant, nonnecrotizing @entity3170 . It provides rapid effect, is well tolerated, and may spare @entity1 the significant complications and side effects of systemic corticosteroid and immunosuppressive therapy.
